Menu footer 1
Menu footer 2
Copyright © 2024 ZEO ScientifiX, INC. All rights reserved. Privacy Policy.
The Most Trusted Source
For Autologous Exosomes
The Most Trusted Source
For Autologous Exosomes
Our ground-breaking research in the field of nanotechnology, specifically extracellular vesicles and perinatal-derived nanoparticles, has created a novel biologic candidate that represents the next frontier of regenerative medicine. ZEO ScientifiX™ is committed to creating life changing and lifesaving therapies for important clinical conditions.
ZEO ScientifiX™ received approval from the U.S. Food and Drug Administration (FDA) for an Investigational New Drug (IND) application on our lead product, Zofin™, for the treatment of knee osteoarthritis. We completed a Phase 1 study for knee osteoarthritis and established the safery of our exosome therapeutics. A double blinded, placebo-controlled, phase II trial investigating the safety and efficacy of Zofin™ for patients suffering with knee osteoarthritis is planned for 2024
ZEO ScientifiX™ received approval from the (FDA) for an Investigational New Drug (IND) application on our lead product, Zofin™, in the treatment of patients diagnosed with COPD. This approved trial design will be a double blinded, placebo-controlled, phase I/II trial investigating the safety and potential efficacy of intravenous infusion (IV) of Zofin™ for the treatment of COPD.
ZEO ScientifiX™ has completed a Phase I in patients with moderate to severe COVID-19 as well as a separate Phase 1 study in patient with “long-haul” COVID-19. The FDA also granted the company an expanded access IND that provided additional patients with COVID-19 access to Zofin outside of the formal clinical trial. This expanded access protocol provides access to Zofin for patients in outpatient and inpatient facilities infected with SARS-CoV-2 who have mild to moderate COVID-19 infection, or who are judged by a healthcare provider to be at high risk of progression to moderate disease. The trial is being conducted at the United Memorial Medical Center in Houston, TX.
ZEO ScientifiX™ is committed to completing our FDA-approved clinical trials as we hope to develop an FDA-approved treatment for multiple clinical conditions.
To pioneer the frontiers of medical science through rigorous research, groundbreaking innovation, and the development of regenerative biologic therapies and nano-technologies to address a broad range of medical conditions.
To pioneer the frontiers of medical science through rigorous research, groundbreaking innovation, and the development of regenerative biologic therapies and nano-technologies to address a broad range of medical conditions.
We Believe We Have Found The Key To Consistent
Patient Outcomes
We Believe We Have Found The Key To Consistent
Patient Outcomes